Arrowhead Pharmaceuticals Stock Alpha and Beta Analysis
| ARWR Stock | USD 13.82 0.02 0.14% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Arrowhead Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Arrowhead Pharmaceuticals over a specified time horizon. Remember, high Arrowhead Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Arrowhead Pharmaceuticals' market risk premium analysis include:
Beta 2.26 | Alpha (0.34) | Risk 3.56 | Sharpe Ratio (0.12) | Expected Return (0.42) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Arrowhead |
Arrowhead Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Arrowhead Pharmaceuticals market risk premium is the additional return an investor will receive from holding Arrowhead Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Arrowhead Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Arrowhead Pharmaceuticals' performance over market.| α | -0.34 | β | 2.26 |
Arrowhead Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Arrowhead Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Arrowhead Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Arrowhead Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Arrowhead Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Arrowhead Pharmaceuticals shares will generate the highest return on investment. By understating and applying Arrowhead Pharmaceuticals stock market price indicators, traders can identify Arrowhead Pharmaceuticals position entry and exit signals to maximize returns.
Arrowhead Pharmaceuticals Return and Market Media
The median price of Arrowhead Pharmaceuticals for the period between Mon, Dec 30, 2024 and Sun, Mar 30, 2025 is 19.02 with a coefficient of variation of 11.3. The daily time series for the period is distributed with a sample standard deviation of 2.08, arithmetic mean of 18.38, and mean deviation of 1.72. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 11520 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 19.05 subject to Rule 16b-3 | 01/02/2025 |
2 | Acquisition by Kenneth Myszkowski of 100000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 01/03/2025 |
3 | Disposition of 10000 shares by Kenneth Myszkowski of Arrowhead Pharmaceuticals at 19.69 subject to Rule 16b-3 | 01/07/2025 |
4 | Disposition of 959 shares by Olukotun Adeoye Y of Arrowhead Pharmaceuticals at 21.0 subject to Rule 16b-3 | 01/23/2025 |
5 | 10,894 Shares in Arrowhead Pharmaceuticals, Inc. Purchased by First Citizens Bank Trust Co. | 01/29/2025 |
6 | Insider Trading | 02/06/2025 |
7 | Arrowhead Pharmaceuticals First Quarter 2025 Earnings Misses Expectations | 02/12/2025 |
8 | What is HC Wainwrights Estimate for ARWR Q2 Earnings | 02/19/2025 |
9 | Arrowhead Pharmaceuticals Unveils Promising Preclinical Results for Obesity Treatment | 02/25/2025 |
10 | Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome | 02/28/2025 |
11 | Disposition of 133333 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 7.75 subject to Rule 16b-3 | 03/03/2025 |
12 | Disposition of 133333 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 17.02 subject to Rule 16b-3 | 03/04/2025 |
13 | Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases | 03/06/2025 |
14 | Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 12 Study of ARO-C3 in Patients with IgA Nephropathy | 03/10/2025 |
15 | Disposition of 51425 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 15.07 subject to Rule 16b-3 | 03/13/2025 |
16 | Arrowhead Pharmaceuticals, Inc. is favoured by institutional owners who hold 70 percent of the company | 03/25/2025 |
About Arrowhead Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Arrowhead or other stocks. Alpha measures the amount that position in Arrowhead Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | |
| Interest Debt Per Share | 1.24 | 4.53 | 5.21 | 4.95 |
| Revenue Per Share | 2.24 | 0.0296 | 0.0341 | 0.0324 |
Arrowhead Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Arrowhead Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arrowhead Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Arrowhead Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Arrowhead Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Arrowhead Pharmaceuticals' management manipulating its earnings.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with Arrowhead Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.